Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic XXXX .

@entity5 @entity1 @entity0 @entity1349
UNASSIGNED: Conventional @entity5 markers have limited value for prognostication and treatment monitoring in @entity0 ( @entity0 ) @entity1 and novel circulating @entity5 markers therefore need to be explored. Hyaluronic acid (HA) is a major macropolysaccharide in the extracellular matrix and is reported to be associated with @entity5 progression. In our study, we investigated plasma HA level with respect to progression free survival (PFS) and @entity1349 ( @entity1349 ), as well as the treatment monitoring value in @entity0 @entity1 . The prognostic value of plasma HA level was investigated in a discovery cohort of 212 @entity0 @entity1 with 2.5-year follow-up and validated in an independent validation cohort of 334 @entity1 with 5-year follow-up. The treatment monitoring value of plasma HA level was investigated in 61 @entity0 @entity1 from discovery cohort who had been radiographically examined after 1(st) complete cycle of chemo therapy. We found a robust association between high plasma HA level and poor prognosis of @entity0 @entity1 in both discovery (pPFS = 7.92 * 10(-6) and pOS = 5.27 * 10(-5) ) and validation studies (pPFS = 3.66 * 10(-4) andpOS = 1.43 * 10(-4) ). In the discovery cohort, the plasma HA level displayed independent prognostic value after adjusted for age and clinicopathological factors, with respect to PFS and @entity1349 . Further, the decrease of plasma HA level displayed good concordance with treatment response evaluated by radiographic examination (AUC=0.79). Plasma HA level displays prognostic value, as well as treatment monitoring value for @entity0 @entity1 . This article is protected by copyright. All rights reserved.
